DYODD.
USA
Joined March 2023
- Tweets3.3K
- Following172
- Followers812
- Likes12K
profitons bien de la jeunesse retweeted
NICHE-2. Keeping it short because the plot speaks for itself.
1. Rename it Chalabi's disease
2. Stop operating on patients first
For those who don't know: 111 patients with locally advanced dMMR colon cancer got one dose of ipi and two of nivo, then surgery. Zero events. A flat line.
Next up? Avoid the surgery altogether.
#ESMO2026
@Onco_Nexus
@OncoAlert @TheGutOncLab
profitons bien de la jeunesse retweeted
Delusional optimism is extremely underrated for mental health.
profitons bien de la jeunesse retweeted
The bottleneck for effective cancer treatment is not the science
"It is no longer the science... that is holding back potential cures, but our capacity to try new medicines in clinical trials."
by @RuxandraTeslo @nytopinion
nytimes.com/2026/09/04/opini…
profitons bien de la jeunesse retweeted
ok but what does my sexual orientation have to do with submitting a paper to science
profitons bien de la jeunesse retweeted
Patrick delete this slandering post immediately or you will face the EU jail
profitons bien de la jeunesse retweeted
a logical move to gain time ahead of competition
Lilly no longer discloses its Phase 1 pipeline, furthering the industry's shielding of drug R&D details as global competition heats up
@endpts spoke w/analysts + former presidents of Lilly Research Labs about the move from the world's largest pharma
endpoints.news/lillys-move-t…
profitons bien de la jeunesse retweeted
I wish it was possible but it’s not. We are not going to “cure most human disease in ~5-10 years.”
profitons bien de la jeunesse retweeted
Breaking: Three sources confirmed to @statnews that the FTC and a group of attorneys general are looking into EHR giant Epic's practices for potential antitrust action.
Read more about the context, including the counts that the FTC is probing on:
statnews.com/2026/08/14/epic…
profitons bien de la jeunesse retweeted
🍿Okay -- we heard you, and we're giving the people what they want: @jrkelly will join me, @PeterKolchinsky + @Fiona_MIT on stage in Boston next week to debate US-China biotech.
In-person only. Tickets link in the tweet below (and we expect to sell out).
🇨🇳💊The China Biotech Debate: Aug. 6 in Boston🧬🇺🇸
Next month we're launching an in-person series on:
➡️How China is changing the definition of innovation
➡️US investors vs US industrial policy
➡️Downstream impact of big pharma's China strategy
events.endpoints.news/the-ch…
profitons bien de la jeunesse retweeted
Administration intends to shift funding away from life sciences to AI and physical sciences:
“At a House hearing, Michael Kratsios echoed points he laid out in a report released Tuesday, titled “Science: A New Golden Age.” He said the administration would prioritize artificial intelligence, robotics and nuclear energy while reducing the government’s focus on what he called “life sciences.”
We won’t see an immediate impact on drug discovery but over 10 years we will start seeing the impact of decreased NIH funding on the rate of new medicines being developed.
nytimes.com/2026/07/22/us/po…
profitons bien de la jeunesse retweeted
Last night at a dinner in Sardinia someone said they don’t like San Francisco because all anyone talks about is AI.
And then we spent the whole dinner talking about AI.
profitons bien de la jeunesse retweeted
Pretty cool
📣 New in #EJC: among PD-(L)1 responders, durability tracks response depth, not tumor type
Our nationwide cohort 🇩🇰: 2,127 responders (#melanoma, #RCC, #NSCLC)
• Within CR & within PR, PFS near-identical across tumors
• PR vs CR = dominant factor
Two papers, two faces of the same coin 🪙:
response depth, not tumor type, drives the risk of acquired resistance to IO
Trial-level (@JNCCN) + real-world (#EJC), same conclusion
Cheers to @DoniaMarco & @CCITdk
Full paper 👇👇
#LCSM #IO
profitons bien de la jeunesse retweeted
US biotechs turn secretive as they fear competition from rising Chinese industry - endpoints.news/us-biotechs-t…
